| Webinar | Host | Action | |
|---|---|---|---|
| Webinars 1 & 2 Obesity / Rare & Chronic Disease |
 |
You will be redirected to the Fierce registration page, where you can register for Webinar 2 or watch Webinar 1 on-demand. Confirmation emails and reminders will be sent by the Fierce events platform. |
Register for Webinar 2 Watch Webinar 1 On-Demand |
| Webinars 3 & 4 Oncology / Women’s Health |
 |
Use the Clarivate form to pre-register for one or both of these sessions. You will receive confirmations and reminders directly from Clarivate. | Pre-register here |
Webinar theme
The chronic disease and inflammation landscape is undergoing profound transformation. Rather than managing symptoms, next-generation precision therapies are increasingly targeting the root immunological drivers of disease, enabling remission discussions and halting progression across multiple therapeutic areas.
This webinar explores four groundbreaking anti-inflammatory and disease-modifying therapies that exemplify this paradigm shift:
Through in-depth clinical and commercial analysis from leading industry specialists at Clarivate, we will examine the pivotal clinical trial evidence, competitive positioning, market impact, and the specific unmet needs each therapy addresses.
Discover how convenient delivery systems, precision mechanisms, and disease-modifying potential are reshaping treatment algorithms—and the commercial and regulatory hurdles each must overcome to achieve blockbuster status.
Register here
Head of Global Thought Leadership, Clarivate
As both a journalist and analyst, Mike has been writing, analyzing and commenting on the life sciences industry for more than 35 years. His actionable insights and analysis support pharma, biotech, healthcare and medtech stakeholders gain a deeper understanding of market news and trends.
Lead Healthcare Research & Data Analyst, VOYXACT (sibeprenlimab) for IgAN
Archita has authored reports on hematological indications, infectious diseases, and rare indications. She holds double master’s degrees in Business Administration and Science with specialization in Biotechnology.
Associate Healthcare Research & Data Analyst (Immune & Inflammation)
Icotrokinra for Plaque Psoriasis. Before joining Clarivate, she was a senior business analyst at AdametNext and holds a master’s in pharmacoinformatics from NIPER.
Senior Manager, Healthcare Research & Data Analytics, Tolebrutinib for Multiple Sclerosis
Mohit Nasa is a Senior Manager on the Immune and Inflammatory team at Clarivate. He holds a Bachelor’s degree in Pharmacy and has earned an MBA in Marketing and CRM from Amity Business School. Prior to joining DRG, Mohit worked as a Senior Business Analyst at Novartis, where he was responsible for end-to-end Market assessment, reporting analytics, and related projects for Novartis’s asthma brand, Xolair.
Healthcare Research & Data Analyst, Depemokimab for Severe Asthma
In his role at Clarivate, Mr. Pareek brings several years of experience in market research. Prior to joining Clarivate, he worked in a market research and consulting firm, where he oversaw several projects in both the pharmaceutical and biotechnology domains.
Webinar theme
As conventional small molecules struggle to modulate so-called “undruggable” targets lacking accessible binding pockets, innovators are increasingly turning to targeted protein degradation (TPD), a modality that harnesses the cell’s intrinsic protein disposal machinery to selectively dismantle pathogenic proteins at their source. The surge of innovation in this space has given rise to a growing number of promising compounds that are positioned to reshape the therapeutic landscape. This webinar explores how TPDs are transforming the industry’s approach to difficult-to-treat diseases, using our Drugs to Watch as examples:
Head of Global Thought Leadership, Clarivate
As both a journalist and analyst, Mike has been writing, analyzing and commenting on the life sciences industry for more than 35 years. His actionable insights support pharma, biotech, healthcare and medtech stakeholders in understanding market trends.
Healthcare Research & Data Analyst
The details about speaker will be shared soon.
Healthcare Research & Data Analyst
The details about speaker will be shared soon.
Originally broadcast: February 11, 2026
Drug focus: Retatrutide & Orforglipron
Kick off the series with a deep dive into the $150bn obesity market. Our analysts will explore next-generation GLP-1 therapies, innovation trends, competitive positioning, and the role of oral vs. injectable treatments.
Click for more details about webinar and speakers▾Webinar 1 theme
The global obesity drug market is accelerating toward a projected $150 billion by 2035, powered by groundbreaking GLP-1 innovation and next-generation metabolic therapies. In this first session of the Drugs to Watch 2026 webinar series, we will unveil the full 2026 report, highlighting 11 therapies expected to reshape treatment paradigms across metabolic disorders, rare diseases, oncology and women’s health.
Head of Global Thought Leadership, Clarivate
As both a journalist and analyst, Mike has been writing, analyzing and commenting on the life sciences industry for more than 35 years. His actionable insights support pharma, biotech, healthcare and medtech stakeholders in understanding market trends.
Lead Healthcare Research & Data Analyst, DRG Commercial Solutions
Shambhavi has authored competitive landscape and market insight reports covering metabolic disorders, with a focus on type 1 diabetes, type 2 diabetes, and GLP-1 RA products. She holds a master’s degree in biotechnology from Amity University.
Analyst, DRG Commercial Solutions, Clarivate
Carles has authored reports on cardiovascular and metabolic indications including obesity, acute coronary syndrome, and hyperkalemia. He previously conducted research at the Francis Crick Institute and IRB Barcelona and holds a Ph.D. in genetics.